Learn the latest about our investigational medicine in development for thyroid eye disease.

Teprotumumab is a fully human monoclonal antibody, insulin-like growth factor-1 receptor (IGF-1R) inhibitor being evaluated for the treatment of active thyroid eye disease (TED).

The robust clinical development program for teprotumumab in the treatment of TED includes positive results from the Phase 3 OPTIC confirmatory clinical trial as well as positive Phase 2 results which were published in The New England Journal of Medicine. The FDA is currently reviewing Horizon’s Biologics License Application. Teprotumumab has received Breakthrough Therapy, Orphan Drug and Fast Track designations from the FDA.

Teprotumumab is an investigational medicine and its safety and efficacy have not been established.

Presentations and Resources

More About Thyroid Eye Disease

For more information about TED, please read our TED Fact Sheet. Physicians can find additional information at TEDImpact.com.

For more information on teprotumumab, please visit clinicaltrials.gov.


  1. The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. European Thyroid Journal.2 March 2016. https://www.ncbi.nlm.nih.gov/pubmed/27099835. Accessed Feb 22, 2019.
  2. Update on thyroid eye disease and management. Clinical Ophthalmology. 19 October 2009. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770865/. Accessed Feb 22, 2019.